Jan Case is Chief Operating Officer of CorriXR Therapeutics, Inc. With over 25 years of experience in the biotechnology and pharmaceutical sectors, Case has driven operational excellence and strategic growth. As president of Cellicon Valley Consulting, she helped biotech start-ups, especially in the cell and gene therapy domains, expand and thrive through strategic fundraising, business development, and R&D optimization. In her previous leadership role at Spark Therapeutics, Case was a key member of the trailblazing team that secured FDA approval for LUXTURNA®, the first gene therapy for a genetic disorder. She also played a pivotal role in Spark’s portfolio and operational expansion. Her career includes over a decade at Shire (now Takeda) in leadership roles in program and portfolio management, and corporate development. Earlier, she was a management consultant and gained extensive product development experience in Europe. Case holds a BSc in Biochemistry and Physiology from Southampton University, an MSc in Medical Informatics from City University/UMDS in London, and has completed an Executive CPD program at Wharton.